| Description | Sotorasib (AMG-510) is an orally active and selective covalent inhibitor of KRAS G12C. Sotorasib binds to the GDP state of the inactive conformation of KRAS G12C and inhibits KRAS and its downstream signaling. Sotorasib exhibits inhibitory activity against KRAS G12C mutant tumors. |
| In vitro | 方法：22 种肿瘤细胞用 Sotorasib (0-10 μM) 处理 72 h，使用 CellTiter-Glo Luminescent Cell Viability Assay kit 检测细胞活力。结果：Sotorasib 损害了除 SW1573 外的所有 KRAS G12C 细胞系的生长，IC50 值范围为 0.004-0.032 μM。非 KRAS G12C 细胞系对 Sotorasib 敏感，IC50>7.5 μM。[1]方法：KRAS G12C 突变肿瘤细胞用 Sotorasib (100 nM) 处理 4-72 h，使用 Western Blot 方法检测靶点蛋白表达水平。结果：Sotorasib 快速抑制 KRAS 下游信号，但 p-ERK 水平在 72 h 回复到基线水平的 75%。[2] |
| In vivo | 方法：为检测体内抗肿瘤活性，将 Sotorasib (3-100 mg/kg) 口服给药给携带人胰腺癌肿瘤 MIA PaCa-2 T2 或人肺癌肿瘤 NCI-H358 的 athymic nude 小鼠，每天一次，持续四周。结果：Sotorasib 在所有剂量下显著抑制 MIA PaCa-2 T2 和 NCI-H358 肿瘤的生长，并且在更高剂量下观察到肿瘤消退。[1]方法：为检测体内抗肿瘤活性，将 Sotorasib (30 mg/kg in 0.5% sodium carboxymethylcellulose，灌胃给药，每天一次) 和 Cisplatin (4 mg/kg in 0.9% saline，腹腔注射，每两天一次) 给药给携带人肺癌肿瘤 H358 的 Balb/C nude 小鼠，持续四周。结果：联合用药组的肿瘤缩小幅度是单一用药组的两倍多。[3] |
| Synonyms | AMG-510 |
| molecular weight | 560.59 |
| Molecular formula | C30H30F2N6O3 |
| CAS | 2296729-00-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: 33.33 mg/mL (59.46 mM), when pH is adjusted to 11 with NaOH. Sonication is recommended. DMSO: 60 mg/mL (107.03 mM), Sonication is recommended. |
| References | 1. Canon J, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 Nov;575(7781):217-223. 2. Ryan MB, et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 2022 Jun 21;39(12):110993. 3. Wu LL, et al. AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research. Discov Oncol. 2023 Jun 7;14(1):91. |
| Citations | 1. Yang N, Fan Z, Sun S, et al.Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation.European Journal of Medicinal Chemistry.2023: 115857. 2. Yun S D, Scott E, Moghadamchargari Z, et al.2′-Deoxy Guanosine Nucleotides Alter the Biochemical Properties of Ras.Biochemistry.2023 3. Wu L L, Jiang W M, Liu Z Y, et al.AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research.Discover Oncology.2023, 14(1): 91. 4. Guo Y, Tian J, Guo Y, et al.Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin.Cell Reports.2023, 42(12). |